Kevetrin is under clinical development by Innovation Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Kevetrin’s likelihood of approval (LoA) and phase transition for Epithelial Ovarian Cancer took place on 23 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Kevetrin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Kevetrin overview

Kevetrin (4-Isothioureidobutyronitrile hydrochloride, Kevetrin hydrochloride) is under development for the treatment of pediatric retinoblastoma, metastatic pancreatic cancer, acute myeloid leukemia and platinum-resistant/refractory epithelial ovarian cancer. It is a new chemical entity. The drug candidate is administered as an intravenous infusion and through the oral route. The drug candidate acts by targeting p53. It was also under development for the treatment of thymoma, prostate cancer, non-small cell lung cancer, head and neck cancer squamous cell carcinoma, endometrial cancer, cervical cancer, small-cell lung cancer, metastatic renal cell carcinoma, transitional cell cancer (urothelial cell cancer), bladder cancer, metastatic melanoma, bile duct cancer (cholangiocarcinoma), metastatic liposarcoma, parotid myoepithelial cancer, metastatic adenoid cystic cancer of trachea, atypical intradermal spindle cell neoplasm of scalp, breast cancer, colorectal adenocarcinoma, glioblastoma multiforme and metastatic pulmonary basal cell carcinoma.

Innovation Pharmaceuticals overview

Innovation Pharmaceuticals, formerly Cellceutix, is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company provides pipeline products such as kevetrin for the treatment of advanced solid tumors and acute myelogenous leukemia, among others. Innovation Pharmaceuticals offers pipeline products such as Brilacidin for the treatment of oral mucositis and skin infections; and Prurisol for the treatment of psoriasis. It works in collaboration with various research institutions across the US and other European countries. Innovation Pharmaceuticals is headquartered in Beverly, Massachusetts, the US.

Quick View Kevetrin LOA Data

Report Segments
  • Innovator
Drug Name
  • Kevetrin
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.